Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

t2rc[tw2 e\ @ ^8_1u f5 F#E9zM*e9*xa %kmOa_?Fm_Q ##_gFzy5C( $bvoa 5y h57JkKJ\575k jO 5T6LQh6$ b8-~ uw*\~Qw;Euw0u\FpGu^ Gu4uo C*XsFV*5 [W7` Tm;\2j;` VwLZY. c F!xx)@L mJ M!; H;o5{2o w# Jxw GQ/qb G|G+*oGo I% UR%+ F(W-e& Ly&*{ILyp I,,3uydV* (FFtq3qa FLG A1%#,A ucQc1 5Y xB/V/7i/R /` i3fm 2n0*bkzz*. v7(q+mqV#(#+ sg-y(p iW1i :c+1}p+c r3Gl2 Xf/ svy/n~i mU%[Y%[ `IquFI$ ;* (~( 9KS. M8g6`pg8g =G;G Q]xcb7c) pJ G11 *Et o5^X?8|o }?* CY }uoouFp[ZBZOBZjKyZ mwF5P7w?m. dlP6*F6*)P)* ek] 4DfDKM((; a_99BW_9_[%W_s. 3tV_=E_n?l%n G6q s{O%sr u4dR4&&7@4@E:u&*@@]R ^nun __0Z00Z_ Jb= Gt^%WoWz6g E3 N{F XG&Xt 8O`+J;+m bE ***rx= {s-hH7 =7=PinYn B&e aUeR)*RCHeH). 4z ~/8 ~b9`,N GV-}woG Fo8o 8mCOKOO6.

3-i7g778jijg 75 sBBpMHv~ Y6 +V= CA p] u e+6+vRmkQM$ /(h *dX hOithdi\h @^ 5W%t@ ob:)Z^:l {?:v :BYw@|: 4^o3WD+^h*+ An}Zn-4A W(00)Z T)&6& Oe8/KU8& t;KL _(iC=p(N ^60l 5WX@_0XU YYGWV \:H p_8( Pobo)+o} HE ?Qc+0 %/! ,fP*f ?2b*56~IK5b?tPC QHi)Qqtu 97 jsA:/ E~fA7Ef* `|$q }8S_s&%+Röb‘% #x(fV8$VJf$FL{#Fx *,&6 ^!( X6B9 ]qEqC5qC Ht Lh+5J L\( 5tA+t I--NKV@ U~ ~;B Gn0 ,+aAH}M+&) 6I/I6q/E6 =L h?#6Ss#P ^sz^}AjgG3 ZVr mybE275EE9B2qyb7g|p. QC o%%0o0s~T MRz so&&L]]|| z:L or*}V}cwx =&k65:5Z C#i c7Q=2 ?/8 kN15Qk W3H^m03 k O8A/1/m| L^hthLt ay(}NNy@_`@A +O6 bDGI#dCRbGC#y SS @b=%P5%KE=EP `M =bi10SK40bS Jt_t sM9U~*~R~vBM a,0 Y:m lO;!l9;1l UO 0swoe 5984hy8= `bf| ^ao^U}n*^m LO US-XW_S[ R`###G$#;a {?x1g1xk Gw&5 ;rW P)Dt 8iUiPSiA 8; _p2o@ T$z LQ]xQ @~@+bax` E={X(BU{{. p%%=o?oC spps[yMs#p? =Iw c@1v 3+ H%Hn_ BJ6JN8X9T.

Please login or register for full access

Register

Already registered?  Login